Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma
INTRODUCTION: Neurokinin-1 receptor (NK-1R) induces inflammatory reactions in peripheral tissues but its regulatory effects in target tissues is dependent on receptor signalling. Substance P (SP) has a high affinity for the NK-1R, to which it binds preferentially. We aimed to investigate the expression of NK-1R in World Health Organization (WHO) grade 4 astrocytomas as well as in oral squamous cell carcinoma (OSCC) and urothelial carcinoma, and its association with disease progression.
MATERIAL AND METHODS: The study included tissue samples from 19 brain astrocytomas, 40 OSCCs and 10 urothelial carcinomas. NK-1R expression was quantitatively assessed in the tumour cells using immunohistochemistry. The relationship between NK-1R expression in astrocytomas and recurrence-free interval has been explored.
RESULTS: The results showed that the NK-1R was intensely expressed in patients with WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. However, cases clinically diagnosed as a low-grade cancer showed reduced NK-1R expression.
CONCLUSIONS: NK-1R is overexpressed in all cases of WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. The ubi-quitous presence of SP/NK-1R complex during tumour development and progression suggests a possible therapeutic key strategy to use NK-1R antagonist as an adjuvant therapy in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Folia neuropathologica - 60(2022), 2 vom: 04., Seite 165-176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mehboob, Riffat [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
33507-63-0 |
|---|
| Anmerkungen: |
Date Completed 12.08.2022 Date Revised 12.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5114/fn.2022.116469 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344698165 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344698165 | ||
| 003 | DE-627 | ||
| 005 | 20231226023357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5114/fn.2022.116469 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344698165 | ||
| 035 | |a (NLM)35950469 | ||
| 035 | |a (PII)47088 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mehboob, Riffat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2022 | ||
| 500 | |a Date Revised 12.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Neurokinin-1 receptor (NK-1R) induces inflammatory reactions in peripheral tissues but its regulatory effects in target tissues is dependent on receptor signalling. Substance P (SP) has a high affinity for the NK-1R, to which it binds preferentially. We aimed to investigate the expression of NK-1R in World Health Organization (WHO) grade 4 astrocytomas as well as in oral squamous cell carcinoma (OSCC) and urothelial carcinoma, and its association with disease progression | ||
| 520 | |a MATERIAL AND METHODS: The study included tissue samples from 19 brain astrocytomas, 40 OSCCs and 10 urothelial carcinomas. NK-1R expression was quantitatively assessed in the tumour cells using immunohistochemistry. The relationship between NK-1R expression in astrocytomas and recurrence-free interval has been explored | ||
| 520 | |a RESULTS: The results showed that the NK-1R was intensely expressed in patients with WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. However, cases clinically diagnosed as a low-grade cancer showed reduced NK-1R expression | ||
| 520 | |a CONCLUSIONS: NK-1R is overexpressed in all cases of WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. The ubi-quitous presence of SP/NK-1R complex during tumour development and progression suggests a possible therapeutic key strategy to use NK-1R antagonist as an adjuvant therapy in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a immunolocalization | |
| 650 | 4 | |a oral squamous cell carcinoma | |
| 650 | 4 | |a substance P | |
| 650 | 4 | |a urothelial carcinoma | |
| 650 | 4 | |a neurokinin-1 receptor | |
| 650 | 7 | |a Receptors, Neurokinin-1 |2 NLM | |
| 650 | 7 | |a Substance P |2 NLM | |
| 650 | 7 | |a 33507-63-0 |2 NLM | |
| 700 | 1 | |a Kurdi, Maher |e verfasserin |4 aut | |
| 700 | 1 | |a Baeesa, Saleh |e verfasserin |4 aut | |
| 700 | 1 | |a Fawzy Halawa, Taher |e verfasserin |4 aut | |
| 700 | 1 | |a Tanvir, Imrana |e verfasserin |4 aut | |
| 700 | 1 | |a Maghrabi, Yazid |e verfasserin |4 aut | |
| 700 | 1 | |a Hakamy, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Saeedi, Rothaina |e verfasserin |4 aut | |
| 700 | 1 | |a Moshref, Rana |e verfasserin |4 aut | |
| 700 | 1 | |a Nasief, Hisham |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Amber |e verfasserin |4 aut | |
| 700 | 1 | |a Waseem, Humaira |e verfasserin |4 aut | |
| 700 | 1 | |a Rasool, Shahida |e verfasserin |4 aut | |
| 700 | 1 | |a Bahakeem, Basem |e verfasserin |4 aut | |
| 700 | 1 | |a Faizo, Eyad |e verfasserin |4 aut | |
| 700 | 1 | |a Katib, Yousef |e verfasserin |4 aut | |
| 700 | 1 | |a Bamaga, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Aldardeir, Nashwa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Folia neuropathologica |d 1996 |g 60(2022), 2 vom: 04., Seite 165-176 |w (DE-627)NLM075030691 |x 1509-572X |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2022 |g number:2 |g day:04 |g pages:165-176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5114/fn.2022.116469 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2022 |e 2 |b 04 |h 165-176 | ||